ALNY - Alnylam Pharmaceuticals, Inc.
| Previous Close | 107.47 |
| Open | 107.71 |
| Bid | 104.72 x 900 |
| Ask | 104.95 x 800 |
| Day's Range | 103.89 - 108.35 |
| 52 Week Range | 70.76 - 153.99 |
| Volume | 441,691 |
| Avg. Volume | 767,271 |
| Market Cap | 10.515B |
| Beta | 3.25 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -5.58 |
| Earnings Date | Aug 7, 2018 - Aug 13, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 148.00 |
Markit•2 days agoSee what the IHS Markit Score report has to say about Alnylam Pharmaceuticals Inc.
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Over the last one-month, outflows of investor capital in ETFs holding ALNY totaled $674 million.
Market Realist•7 days agoHow Analysts Are Rating Puma Biotechnology in July
The positive recommendation from CHMP comes after a reexamination of negative recommendations at the meeting for the MAA on February 23. On July 5, the company had a consensus 12-month target price of $94.17, which represents a 60.29% return on investment over the next 12 months. On July 5, Incyte had a consensus 12-month target price of $83.71, which represents an 18.65% return on investment over the next 12 months.
Markit•9 days agoSee what the IHS Markit Score report has to say about Alnylam Pharmaceuticals Inc.
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.
- Benzinga•10 days ago
Analyst Downgrades Arbutus Biopharma On Valuation After 80% Run
Arbutus Biopharma Corp (NASDAQ: ABUS ) stock has gained 80 percent since the turn of the year, and B. Riley FBR dropped its bullish stance Friday in the wake of the rally. The Analyst B. Riley FBR's ...
- Investor's Business Daily•11 days ago
Why This Biotech Company 'Dominates' Its Rival In Drug Study
Alnylam seemingly outperformed rival Ionis in tests of drugs to treat a progressive rare disease, an analyst said Thursday. Both biotech companies are making treatments for a condition known as hereditary ATTR amyloidosis.
- Business Wire•12 days ago
Alnylam Announces Publication of APOLLO Phase 3 Clinical Study Results for Investigational RNAi Therapeutic Patisiran in The New England Journal of Medicine
Alnylam Pharmaceuticals, Inc. (ALNY), the leading RNAi therapeutics company, announced today that the pivotal study results from the APOLLO Phase 3 trial of patisiran were published online today in The New England Journal of Medicine (NEJM). The study showed that patisiran improved measures of polyneuropathy, quality of life, activities of daily living, ambulation, nutritional status, and autonomic symptoms relative to placebo in patients with hereditary transthyretin-mediated (hATTR) amyloidosis, an inevitably progressive and generally fatal disease. Further, the frequency and severity of adverse events (AEs) were similar in patients receiving patisiran and placebo, with the exception of peripheral edema and infusion-related events which were higher in patisiran-treated patients and generally mild to moderate in severity.
- Zacks•18 days ago
Medicines Company's Inclisiran Studies to Continue Unmodified
The Medicines Company (MDCO) announces that Independent Data Monitoring Committee has recommended that the ongoing phase III studies of its candidate, inclisiran, will continue without modification.
- GlobeNewswire•19 days ago
Report: Developing Opportunities within Valvoline, Parker Drilling, Dean Foods, BioPharmX, Hasbro, and Alnylam Pharmaceuticals — Future Expectations, Projections Moving into 2018
NEW YORK, June 27, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Valvoline ...
- Business Wire•25 days ago
Alnylam to Host Fifth Annual “RNAi Roundtable” Webcast Series
Alnylam Pharmaceuticals, Inc. (ALNY), the leading RNAi therapeutics company, announced today that it plans to host its 5th annual series of “RNAi Roundtable” webcasts this summer. The 2018 series will offer a range of presentations from Alnylam scientists, clinical collaborators, and patients or patient advocates, who will review recent progress in many of the Company’s late-stage pipeline programs and platform.
- Market Realist•26 days ago
Caladrius Biosciences’ Stock Price Rose 67% on June 19
On June 19, Caladrius Biosciences’ stock price rose 67.3% and reached $6.61 from the previous close of $3.95 on June 18.
- Business Wire•26 days ago
Alnylam Expands Senior Leadership Team with Two Key Appointments
Alnylam Pharmaceuticals, Inc. (ALNY), the leading RNAi therapeutics company, announced today the appointments of two accomplished biotech executives, Masako Nakamura as Senior Vice President, Head of Asia, and Jing L. Marantz, M.D., Ph.D., as Senior Vice President, Head of Medical Affairs. "We are pleased to have Masako and Jing join us at an exciting crossroads in Alnylam’s journey from an R&D to a commercial organization.
- Business Wire•last month
Alnylam to Report New Clinical Results for Patisiran at the 4th Congress of the European Academy of Neurology
Alnylam Pharmaceuticals, Inc. , the leading RNAi therapeutics company, today announced that additional results from the APOLLO Phase 3 study of patisiran, an investigational RNAi therapeutic for the treatment of hereditary ATTR amyloidosis, will be presented at the 4th Congress of the European Academy of Neurology , being held June 16-19, 2018 in Lisbon, Portugal.
- ACCESSWIRE•last month
Today's Research Reports on Trending Tickers: Alnylam Pharmaceuticals and Intercept Pharmaceuticals
NEW YORK, NY / ACCESSWIRE / June 13, 2018 / U.S. markets were relatively quiet following the summit between President Donald Trump and North Korean leader Kim Jong Un in Singapore. The Dow Jones Industrial ...
- Business Wire•last month
Over 700 Alnylam Employees Volunteer at the Company’s 4th Annual “Helping Hands” Community Service Day
Alnylam Pharmaceuticals, Inc. , the leading RNAi therapeutics company, today kicked off its fourth annual company-wide “Helping Hands” Community Service Day benefiting 23 organizations, including 16 organizations in the Greater Boston area and seven organizations in Western Europe.
- ACCESSWIRE•last month
Wired News – Alnylam Pharma Presented New Encouraging Results from Phase-1/2 Study of Lumasiran in Patients with Primary Hyperoxaluria Type-1
LONDON, UK / ACCESSWIRE / June 12, 2018 / If you want access to our free research report on Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=ALNY as the Company’s latest news hit the wire. On June 08, 2018, the Company presented updated positive results from its Phase-1/2 study assessing lumasiran for the treatment of Primary Hyperoxaluria Type-1 (PH1) at the OxalEurope, European Hyperoxaluria Consortium in Naples, Italy. Active-Investors.com is currently working on the research report for Cleveland BioLabs, Inc. (NASDAQ: CBLI), which also belongs to the Healthcare sector as the Company Alnylam Pharma.
- Zacks•last month
Alnylam Reports Positive Data on Lumasiran in Renal Disease
Alnylam (ALNY) announces positive results from the ongoing study on lumasiran in Primary Hyperoxaluria Type 1 (PH1) patients.
- ACCESSWIRE•last month
Stock Performance Review on Alder Biopharma and Three Other Biotech Stocks
LONDON, UK / ACCESSWIRE / June 11, 2018 / If you want a free Stock Review on ALDR sign up now at www.wallstequities.com/registration. Gains were broad based as seven out of nine sectors finished the trading session in green. WallStEquities.com has initiated research reports on the following Biotechnology stocks: Alder Biopharmaceuticals Inc. (NASDAQ: ALDR), Alexion Pharmaceuticals Inc. (NASDAQ: ALXN), Alnylam Pharmaceuticals Inc. (NASDAQ: ALNY), and Altimmune Inc. (NASDAQ: ALT).
Markit•last monthSee what the IHS Markit Score report has to say about Alnylam Pharmaceuticals Inc.
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.
- Business Wire•last month
Alnylam Reports Updated Positive Results from Phase 1/2 Study of Lumasiran in Patients with Primary Hyperoxaluria Type 1 (PH1)
Alnylam Pharmaceuticals, Inc. (ALNY), the leading RNAi therapeutics company, announced today new positive results from its Phase 1/2 study with lumasiran, an investigational RNAi therapeutic targeting glycolate oxidase (GO) for the treatment of Primary Hyperoxaluria Type 1 (PH1). Results were presented at the OxalEurope, European Hyperoxaluria Consortium, taking place on June 8, 2018 in Naples, Italy. Part B is a randomized (3:1 drug:placebo), single-blind, placebo-controlled evaluation of lumasiran in patients with PH1.
- Motley Fool•last month
3 Top Biotech Stocks to Buy in June
The cure for your portfolio's ills might be found in these three mid-cap biotech stocks.
- Business Wire•last month
Alnylam Receives Orphan Drug Designation from the United States Food & Drug Administration for ALN-TTRsc02, a Subcutaneously Delivered Investigational RNAi Therapeutic for the Treatment of Transthyretin-Mediated Amyloidosis
Alnylam Pharmaceuticals, Inc. (ALNY), the leading RNAi therapeutics company, announced today that the United States Food and Drug Administration (FDA) has granted Orphan Drug Designation to ALN-TTRsc02, an investigational RNAi therapeutic for the treatment of transthyretin-mediated amyloidosis. “We are very pleased to have received Orphan Drug Designation from the FDA for ALN-TTRsc02, which we believe has the potential to become a meaningful treatment option for people living with ATTR amyloidosis, a progressive, debilitating, and often fatal disease,” said Rena Denoncourt, Program Leader, ALN-TTRsc02 Program at Alnylam. The FDA Orphan Drug Designation Program provides orphan status to drugs and biologics which are defined as those intended for the safe and effective treatment, diagnosis or prevention of rare diseases/disorders that affect fewer than 200,000 people in the U.S.
- Zacks•last month
Why Is Alnylam (ALNY) Up 12.6% Since Its Last Earnings Report?
Alnylam (ALNY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Motley Fool•last month
Better Buy: Bellicum Pharmaceuticals, Inc. vs. Alnylam Pharmaceuticals, Inc.
Which stock wins in a battle between these two clinical-stage biotechs with regulatory approvals potentially just around the corner?
Market Realist•2 months agoThe Upside Potential in Editas Medicine Stock
Editas has key collaboration agreements with Juno Therapeutics and Allergan Pharmaceuticals. Of the nine analysts covering Editas Medicine in May, five have given the stock “buy” or higher ratings, three have given it “hold” ratings, and one has given it a “strong sell” rating. The mean rating for the stock is 2.67, and its target price is $45.2, implying an upside potential of 23.4% over its closing price of $36.63 on May 24.
- Business Wire•2 months ago
Alnylam to Webcast Presentations at Upcoming June Investor Conferences
Alnylam Pharmaceuticals, Inc. , the leading RNAi therapeutics company, announced today that management will present company overviews at the following conferences:
